pipeline news from FiercePharma
NewsSilver lining to Big Pharma's cloud?
Some people see the Big Pharma glass as half-full instead of the alternative. In an investor's-eye look at the industry, Kiplinger ticks off the usual criticisms: patent expirations, tough generics Read more...
Takeda risks short-term pain in buyout
You can't say Takeda Pharmaceutical is unwilling to take risks. The Japanese drugmaker went out on an $8.8 Read more...
Vasella touts Novartis' diversification
Novartis CEO Daniel Vasella (photo) talked up his company's prospects in an interview with the Swiss weekly Sonntag, Read more...
Takeda offers $8.8B for Millennium
Takeda Pharmaceutical is placing an $8.8 billion bet on cancer meds. The Japanese drugmaker has offered $25 per share for Millennium Pharmaceuticals, which not only makes the lucrative blood-cancer Read more...
AstraZeneca rivals could launch any day
You can bet the execs at AstraZeneca are biting their nails this week. Next Monday, April 14, marks the end of a 30-month stay on Ranbaxy Laboratories' copycat form of the mega-blockbuster Nexium. Read more...
FDA: Expect more early warnings
The FDA is warning consumers to expect more communiques about drug side effects. As we noted last week, the number of "early communications" has increased recently, reflecting a new policy of Read more...
SPOTLIGHT: MabThera aims for new indications
Roche's antibody med MabThera (Rituxan) just aced two trials aimed at expanding uses for the drug: one that pitted MabThera against rheumatoid arthritis and another that used it against adult Read more...
ImClone goes long on Erbitux
Is all the Erbitux hype warranted? Some industry analysts say yes, others say they're skeptical. The right answer carries big stakes, because ImClone Systems has all its short-term eggs in that Read more...
The top 15 R&D budgets
In the world of drug development, you're only as good as your pipeline. As many companies' older blockbuster drugs go off-patent, analysts are looking at pipelines to see who'll have what it takes to Read more...
SPOTLIGHT: Pfizer snaps up Coley Pharma
Pfizer plans to buy Coley Pharmaceuticals in a $164 million tender offer, hoping to reap new products from Coley's pipeline of vaccine and immunotherapy candidates. Read more...
| Press ReleasesPRESS RELEASE: GlaxoSmithKline presents innovative neuroscience pipeline GlaxoSmithKline presents innovative neuroscience pipeline Issued on Thursday 13 December 2007 - LSE announcement - GlaxoSmithKline (GSK) plc today presented an overview of its neuroscience portfolio Read more... PRESS RELEASE: Merck Reviews Progress on Strategic Plan at 2007 Annual Business Briefing Merck Reviews Progress on Strategic Plan at 2007 Annual Business Briefing Merck's Pipeline Continues to Progress with Seven Products in Phase III Development Company Expects to File Applications Read more... PRESS RELEASE: Sanofi- aventis: A Promising R&D Portfolio, Well Positioned to Deliver Future Growth Sanofi-aventis: A Promising R&D Portfolio, Well Positioned to Deliver Future Growth PARIS, Sept. 17, 2007--Sanofi-aventis today made announced it plans to have 31 potential submissions by the Read more... |
Get more pipeline coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight